The US Centers for Medicare and Medicaid Services will not impose a plan requiring wholesalers and manufacturers of selected high-cost drugs, including cell and gene therapies, to disclose how prices are set for Medicaid, a recently-released final rule on various Medicaid drug rebate program issues states.
CMS Withdraws Medicaid Cell, Gene Therapy Price ‘Verification’ Survey Plan
The move is positive for manufacturers and follows the agency’s decision to drop another contentious proposal that would have ‘stacked’ drug discounts when calculating Medicaid best prices.
More from Market Access
More from Pink Sheet
• By
One CDRH employee said the cuts already are having a major effect on morale.
• By
Mass FDA layoffs on 1 April were designed to spare product reviewers, but still touched many who are critical to the application review process or drug development, which could mean fewer treatments are brought to the US market first.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.